Newsroom > Denis DELVAL is appointed President and CEO of the Ethypharm Group
Monday 10 October 2022 - 12h15
Denis DELVAL is appointed President and CEO of the Ethypharm Group
Saint-Cloud – France – 10 October 2022. The Supervisory Board appointed Denis DELVAL as President and CEO of the Ethypharm Group.
Denis DELVAL, Doctor of Pharmacy, graduate of ESSEC, has an impressive range of experience in the pharmaceutical industry where he has spent his entire career in France and internationally in large and medium-sized groups (Bayer, Fournier Pharma, ALK, LFB).
He has held positions of increasing importance in marketing, sales, strategy and general management, notably at ALK, the leading Danish company in allergy desensitisation treatments, where he was responsible for the French subsidiary and then Senior Vice-President Europe.
In 2017, he was appointed President of LFB, a biopharmaceutical group that develops, manufactures and markets medicinal products derived from living matter. He has profoundly changed the company and has committed it at all levels to a transformation process based on shared values.
"I am proud to join Ethypharm, a European company with French roots, specialising in Central Nervous System (CNS) diseases and hospital injectables. I look forward to mobilising energies and continuing the development of the Group", Denis DELVAL announced.
About the Ethypharm Group
Ethypharm is a European pharmaceutical company specialising in two areas: the Central Nervous System and Hospital Injectable Medicines. Ethypharm markets its medicines directly in Europe and China, and works with partners in North America and the Middle East where its medicines are in high demand. The Group employs more than 1,750 people, mainly based in Europe and China.
Ethypharm works closely with the authorities and health professionals to ensure the appropriate use of and access to its medicines for as many people as possible.